# A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice

> **NCT05192642** · — · COMPLETED · sponsor: **Bayer** · enrollment: 368 (actual)

## Conditions studied

- Solid Tumors Harboring NTRK Fusion

## Interventions

- **DRUG:** Larotrectinib(Vitrakvi, BAY2757556)
- **DRUG:** Data on other treatments

## Key facts

- **NCT ID:** NCT05192642
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-03
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-08-31
- **Target enrollment:** 368 (ACTUAL)
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05192642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05192642, "A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05192642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*